Zota Healthcare applies for patent in pain management
The Rs 50-crore Surat-based pharmaceutical company Zota Healthcare which has
already applied for a patent on RTFIT, it liver fitness formulation, has applied
for another patent, this time for a oral formulation of paracetamol, which claims
can cure high grade fever via oral doses and injection as well.
Talking about the new innovation and patent filing, Dr Sanjay Agrawal, Medical
Consultant, Zota Healthcare said, After intensive research over the last
three years, we have developed a new product for pain management. This unique
and novel formulation will help to reduce pain in a more advanced manner. These
innovations are in the final stages and will be soon introduced in the Indian
Agrawal further said that their research resulted in a superior formulation
of paracetamol, which is more soluble, stable, bioavailable and is pleasantly
tasting. Further, with this technology, the parenteral form will be less viscous,
more stable with reduced chances of precipitation during storage and processing
and is easily administrable even at higher concentrations of paracetamol with
lesser chances of thrombus formation, claims Agarwal.
Paracetamol is an antipyretic that can reduce fever by affecting the part of
the brain known as the hypothalamus, which regulates the temperature of the
body. This is why paracetamol is included in many cough, cold and flu medications.
It is sparingly soluble drug with bitter taste and requires around half an hour
to start its action after oral administration. Further, the low solubility in
conventional injectable form can cause a viscous solution and thrombus formation
at the site of intravenous injection. Without these limitations, paracetamol
can be a better drug with a difference. Hence Zota believes the process innovation
Meanwhile, work on the existing product in the market, RTFIT, continues. Citing
clinical trials results, Agrawal highlighted, RTFIT has undergone many
pre-and post-launch clinical trials and all the trials have proven the unmatched
benefits for patients suffering from alcoholic liver diseases, hepatitis, toxic
liver diseases and so on. The overwhelming response for RTFIT from all corners
has paved the way for many such further innovations.
Speaking about company's plans for an IPO and corporate strategy going forward,
Ketan Zota, Managing Director, Zota Healthcare said, We are in the process
of hiring an agency who will look after all IPO filing related activities and
we are hopeful that by early next year we shall be able to file the Draft Red
Herring Prospectus (DRHP). Recently, we have commissioned our new plant at Surat
SEZ and with the help of this new plant, we are targeting a turnover of Rs 80
crore, up from the current Rs 50 crore, in financial year 2011-12. We are also
aiming to achieve over Rs 100 crore turnover by 2013.
Zota Healthcare has a manpower strength of 225 and plans to increase its headcount
by 50 per cent each year. The company is in the process of applying to WHO
Geneva, and TGA Australia for approvals. Once it receives these approvals,
it will apply for US FDA approval.